We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App





Production of High-Quality Antibodies Continues 5-7 Months After SARS-CoV-2 Infection, Finds New Study

By HospiMedica International staff writers
Posted on 14 Oct 2020
Print article
Image: Production of High-Quality Antibodies Continues 5-7 Months after SARS-CoV-2 Infection, Finds New Study (Photo courtesy of University of Arizona Health Sciences)
Image: Production of High-Quality Antibodies Continues 5-7 Months after SARS-CoV-2 Infection, Finds New Study (Photo courtesy of University of Arizona Health Sciences)
A study of the production of antibodies from a sample of nearly 6,000 people who recovered from COVID-19 has revealed that immunity persists for at least several months after being infected with SARS-CoV-2.

One of the most significant questions about the novel coronavirus is whether people who are infected are immune from reinfection and, if so, for how long. When a virus first infects cells, the immune system deploys short-lived plasma cells that produce antibodies to immediately fight the virus. Those antibodies appear in blood tests within 14 days of infection. The second stage of the immune response is the creation of long-lived plasma cells, which produce high-quality antibodies that provide lasting immunity.

Researchers from the University of Arizona Health Sciences (Tucson, AZ, USA) tracked antibody levels over several months in people who tested positive for SARS-CoV-2 antibodies. The team also developed a blood test to check for SARS-CoV-2 antibodies by employing two different parts of the SARS-CoV-2 virus - S1 and S2. Most tests look for antibodies at S1, which includes the receptor-binding domain wherein the spike protein binds to a protein receptor to infect cells. The UArizona Health Sciences test also analyzes the S2 region of the spike protein. Antibodies must be present in both locations for the test to be determined positive.

For the study, 5,882 volunteers underwent antibody testing using the UArizona Health Sciences test. The researchers found SARS-CoV-2 antibodies are present in blood tests at viable levels for at least five to seven months, although they believe immunity lasts much longer. Earlier studies had extrapolated antibody production from initial infections and suggested antibody levels drop quickly after infection, providing only short-term immunity. The UArizona Health Sciences researchers believe that those conclusions focused on short-lived plasma cells and failed to take into account long-lived plasma cells and the high-affinity antibodies they produce.

“We clearly see high-quality antibodies still being produced five to seven months after SARS-CoV-2 infection,” said Deepta Bhattacharya, PhD, associate professor, UArizona College of Medicine – Tucson, Department of Immunobiology. “Many concerns have been expressed about immunity against COVID-19 not lasting. We used this study to investigate that question and found immunity is stable for at least five months.”

“Whether antibodies provide lasting protection against SARS-CoV-2 has been one of the most difficult questions to answer,” said UArizona Health Sciences Senior Vice President Michael D. Dake, MD, who is a co-author on the paper. “This research not only has given us the ability to accurately test for antibodies against COVID-19, but also has armed us with the knowledge that lasting immunity is a reality.”

Related Links:
University of Arizona Health Sciences

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Gold Member
X-Ray QA Meter
T3 AD Pro
New
Cannulating Sphincterotome
TRUEtome
New
In-Bed Scale
IBFL500

Print article

Channels

Surgical Techniques

view channel
Image: The new treatment combination for subdural hematoma reduces the risk of recurrence (Photo courtesy of Neurosurgery 85(6):801-807, December 2019)

Novel Combination of Surgery and Embolization for Subdural Hematoma Reduces Risk of Recurrence

Subdural hematomas, which occur when bleeding happens between the brain and its protective membrane due to trauma, are common in older adults. By 2030, chronic subdural hematomas are expected to become... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.